Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;57(5):742-752.
doi: 10.1038/s41409-022-01604-x. Epub 2022 Feb 22.

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey

Jakob R Passweg  1 , Helen Baldomero  2 , Christian Chabannon  3 , Selim Corbacioglu  4 , Rafael de la Cámara  5 , Harry Dolstra  6 , Bertram Glass  7 , Raffaella Greco  8 , Mohamad Mohty  9 , Bénédicte Neven  10 , Régis Peffault de Latour  11 , Zinaida Perić  12 , John A Snowden  13 , Ibrahim Yakoub-Agha  14 , Anna Sureda  15 , Nicolaus Kröger  16 ; European Society for Blood and Marrow Transplantation (EBMT)
Affiliations

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey

Jakob R Passweg et al. Bone Marrow Transplant. 2022 May.

Abstract

In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous in 690 centers were reported. Changes observed were as follows: total number of HCT -6.5%, allogeneic HCT -5.1%, autologous HCT -7.5%, and were more pronounced in non-malignant disorders for allogeneic HCT and in autoimmune disease for autologous HCT. Main indications were myeloid malignancies 10,441 (25%), lymphoid malignancies 26,120 (64%) and non-malignant disorders 2532 (6%). A continued growth in CAR-T cellular therapies to 1874 (+65%) patients in 2020 was observed. In allogeneic HCT, the use of haploidentical donors increased while use of unrelated and sibling donors decreased. Cord blood HCT increased by 11.7% for the first time since 2012. There was a significant increase in the use of non-myeloablative but a drop in myeloablative conditioning and in use of marrow as stem cell source. We interpreted these changes as being due to the SARS-CoV-2 pandemic starting early in 2020 in Europe and provided additional data reflecting the varying impact of the pandemic across selected countries and larger cities. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual report of the EBMT reflects current activities useful for health care planning.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. The absolute numbers of patients who received their first transplant during the years 1990–2020.
Absolute number of patients receiving a 1st HCT 1990–2020.
Fig. 2
Fig. 2. Relative proportion of disease indications for HCT in Europe 2020.
a Relative proportion of allogeneic HCT. b Relative proportion of autologous HCT.
Fig. 3
Fig. 3. The change in the numbers of myeloablative versus non-myeloablative allogeneic HCT performed in Europe during the years 2000–2020.
Change in the numbers of MAB versus NMA HCT in Europe 2000–2020.
Fig. 4
Fig. 4. The changes seen in the choice of donor during the years 1990–2020.
Change in choice of donor type from 1990 to 2020.
Fig. 5
Fig. 5. The change in the absolute numbers of autologous HCT reported for lymphoproliferative disorders during the years 1990–2020.
Change in the absolute numbers of autologous HCT for lymphoproliferative disorders from 1990 to 2020.
Fig. 6
Fig. 6. The absolute numbers of CAR-T therapies by donor type reported during the years 2018–2020.
Absolute numbers of CAR-T therapies by donor type 2018–2020.
Fig. 7
Fig. 7. Average change in the number of transplants in centers reporting consistently over the 4-year period 2017–2020.
Take note of the changing scale on the Y-axis. a Average change in the number of transplants in selected countries. b Average change in the number of transplants in selected cities with more than five reporting centers.
See this image and copyright information in PMC

References

    1. Gratwohl A. Bone marrow transplantation activity in Europe 1990. Report from the European Group for Bone Marrow Transplantation (EBMT) Bone Marrow Transpl. 1991;8:197–201. - PubMed
    1. Copelan EA, Chojecki A, Lazarus HM, Avalos BR. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev. 2019;34:34–44. doi: 10.1016/j.blre.2018.11.001. - DOI - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472–5. doi: 10.1056/NEJMp078166. - DOI - PubMed
    1. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54:1525–52. doi: 10.1038/s41409-019-0516-2. - DOI - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. doi: 10.1001/jama.2010.491. - DOI - PMC - PubMed

Publication types